Literature DB >> 2680032

Neuropsychological assessment of the severely impaired elderly patient.

J Saxton1, A A Swihart.   

Abstract

Although a number of standard scales exist for the assessment of the mildly to moderately demented patient, measurement of cognitive decline needs to be extended beyond this stage and into the range of functioning characteristic of the severely impaired individual. To do this, assessment techniques need to be developed which take into account the specific behavioral and cognitive deficits seen in severe dementia. Until such techniques are developed. a full and adequate account of the natural history of cognitive decline in AD is not possible. We have introduced a new assessment device, the Severe Impairment Battery, which evaluates a range of cognitive functioning in patients who are unable to complete standard neuropsychological tests. Preliminary results with this test are encouraging and suggest that, contrary to popular belief, many severely cognitively impaired patients are testable if appropriate techniques and strategies are applied.

Entities:  

Mesh:

Year:  1989        PMID: 2680032

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  12 in total

1.  Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.

Authors:  F A Schmitt; J Saxton; S H Ferris; J Mackell; Y Sun
Journal:  Int J Clin Pract       Date:  2013-10       Impact factor: 2.503

2.  Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

Authors:  Philippe Robert; Steven Ferris; Serge Gauthier; Ralf Ihl; Bengt Winblad; Frank Tennigkeit
Journal:  Alzheimers Res Ther       Date:  2010-08-26       Impact factor: 6.982

Review 3.  Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease.

Authors:  Gregory A Jicha; Sarah A Carr
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Additive scales in degenerative disease--calculation of effect sizes and clinical judgment.

Authors:  Matthias W Riepe; David Wilkinson; Hans Förstl; Andreas Brieden
Journal:  BMC Med Res Methodol       Date:  2011-12-16       Impact factor: 4.615

5.  Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice.

Authors:  Vjera A Holthoff; Steven Ferris; Ralf Ihl; Philippe Robert; Bengt Winblad; Serge Gauthier; Kati Sternberg; Frank Tennigkeit
Journal:  Alzheimers Res Ther       Date:  2011-07-06       Impact factor: 6.982

Review 6.  On the path to 2025: understanding the Alzheimer's disease continuum.

Authors:  Paul S Aisen; Jeffrey Cummings; Clifford R Jack; John C Morris; Reisa Sperling; Lutz Frölich; Roy W Jones; Sherie A Dowsett; Brandy R Matthews; Joel Raskin; Philip Scheltens; Bruno Dubois
Journal:  Alzheimers Res Ther       Date:  2017-08-09       Impact factor: 6.982

Review 7.  Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.

Authors:  Jeffrey Cummings; Aaron Ritter; Kate Zhong
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

8.  What are we trying to prevent in Alzheimer disease?

Authors:  Frank Jessen
Journal:  Dialogues Clin Neurosci       Date:  2019-03       Impact factor: 5.986

9.  Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia.

Authors:  Philip E Lee; Sudeep S Gill; Paula Rochon
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

10.  Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients.

Authors:  Lídia Blanco-Silvente; Dolors Capellà; Josep Garre-Olmo; Joan Vilalta-Franch; Xavier Castells
Journal:  BMC Geriatr       Date:  2018-07-24       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.